eva-1 encodes, by alternative splicing, two isoforms of a cell-surface protein that acts cell-autonomously with SAX-3 as a SLT-1 receptor subunit, and is required for guidance of the AVM pioneer axon to the ventral nerve cord; EVA-1's long isoform is predicted to have a signal sequence, an ectodomain with two lectinlike galactose-binding sequences, a single transmembrane sequence, and a cytodomain with a phosphotyrosine binding motif; homologs of EVA-1 include human C21orf63; EVA-1 is expressed in embryonic neurons during axonal growth, head and tail neurons, the ventral nerve cord, pharyngeal and body wall muscles, hypodermis, uterus and vulva; ectopic EVA-1 expression in touch-receptor neurons causes the cell body of ALM to be displaced anteriorly (due to failed posterior migration) in a SLT-1-dependent manner; the cytodomain of EVA-1 is functionally dispensable in vivo; eva-1 mutants enhance the ventral-axon guidance defects of unc-40 mutants; EVA-1, SLT-1, and SAX-3 bind one another in vitro.
Predicted to enable carbohydrate binding activity. Located in M band; cell junction; and striated muscle dense body. Expressed in body wall musculature; hypodermis; pharyngeal muscle cell; and ventral nerve cord. Is an ortholog of human EVA1C (eva-1 homolog C).
Map position created from combination of previous interpolated map position (based on known location of sequence) and allele information. Therefore this is not a genetic map position based on recombination frequencies or genetic experiments. This was done on advice of the CGC.